These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 28673936)

  • 1. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the HGF/Met signalling pathway in cancer.
    Cecchi F; Rabe DC; Bottaro DP
    Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
    Cecchi F; Rabe DC; Bottaro DP
    Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression array analysis of the hepatocyte growth factor invasive program.
    Cecchi F; Lih CJ; Lee YH; Walsh W; Rabe DC; Williams PM; Bottaro DP
    Clin Exp Metastasis; 2015 Oct; 32(7):659-76. PubMed ID: 26231668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
    Wang X; Le P; Liang C; Chan J; Kiewlich D; Miller T; Harris D; Sun L; Rice A; Vasile S; Blake RA; Howlett AR; Patel N; McMahon G; Lipson KE
    Mol Cancer Ther; 2003 Nov; 2(11):1085-92. PubMed ID: 14617781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
    Yap TA; Sandhu SK; Alam SM; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the c-MET signaling pathway for cancer therapy.
    Liu X; Yao W; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
    Liu D; Zhong M; Zhan D; Zhang Y; Liu S
    Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
    Li Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the structure address on MET receptor activation by HGF.
    Linossi EM; Estevam GO; Oshima M; Fraser JS; Collisson EA; Jura N
    Biochem Soc Trans; 2021 Apr; 49(2):645-661. PubMed ID: 33860789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.